Pregnancy in CADASIL
Probably because of the relatively high frequency of stroke in CADASIL patients, in Italy general physicians and gynecologists consider pregnant women carrying a NOTCH3 mutation at high risk of systemic vascular events or placental damage; therefore, they frequently prescribe those patients with antithrombotic drugs during pregnancy. Because of the low prevalence of the disease and the few data about pregnancy outcome in CADASIL patients,7 it is difficult to give advice on the use of these drugs to CADASIL women who are planning a pregnancy. Furthermore, there are no reports of pregnancy outcome in women with CADASIL in comparison with healthy women.
The aim of this paper was to report our experience concerning pregnancies in a CADASIL patient population. Data reported in this review are based on two series of CADASIL patients. The first one is composed of patients in whom the diagnosis of CADASIL was unknown at the time of pregnancy and who came to our attention and were diagnosed some time after. The second group is that of patients in whom the diagnosis was already known at the time of the pregnancy beginning and could therefore be followed during gestation.